TLX Financials

Income Statement
MetricQ3 2010Q2 2010
Revenue
7.1M
+12.8%
6.3M
Cost of Revenue
5.8M
+14.1%
5.1M
Gross Profit
1.3M
+7.6%
1.2M
Operating Expenses
2.1M
-38.4%
3.4M
R&D
—
—
SG&A
2.0M
-13.8%
2.3M
Operating Income
-836000
+62.4%
-2226000
EBITDA
540.0K
+145.6%
-1184000
Net Income
-1230000
+52.8%
-2605000
EPS (Basic)
$-0.01
+66.7%
$-0.03
EPS (Diluted)
$-0.01
+66.7%
$-0.03
Shares (Diluted)
97.7M
+0.0%
97.7M
Telix Pharmaceuticals Limited American (TLX) — Financials